Clinical evaluation of Pathyadi Kwatha and Anu Taila Nasya in the management of Ardhavabhedaka (Migraine). - Migraine

Central Council For Research In Ayurvedic SciencesCCRAS0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients of either sex aged in between 18 to 60 years.
•2.Diagnosed cases of Migraine with aura /without aura as per as per International Headache Society-ICHD-III (International classification of Headache Disorders 3rd version).
•3.Patients with up to Grade III on MIDAS Scale.
•4.Frequency of headache is > two times in a month.
•5.Willing and able to participate for 3 months (consent to be obtained from patients).

•1.Patients who were suffering with headache due to space occupying lesions and other secondary reasons.
•2.Patients with severe infection and/or clinically significant respiratory, cardiac or haematological disorders.
•3.Hypertensive patients who are on Î² blockers.
•4.Patients with uncontrolled Diabetes mellitus (HbA1C >8%).
•5.Patients with uncontrolled Hypothyroidism (S.TSH >10mIU/ml).
•6.Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT >3 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.4 mg/dl)
•7.Alcoholics and/or drug abusers.
•8.Known cases of malignancy.
•9.Pregnant women or planning to conceive or lactating woman.
•10.Patients in whom another investigational drug was used within 3 months prior to entry in this study.
•11.Any other condition, which the PI thinks, may jeopardize the study.

发起方

Central Council For Research In Ayurvedic SciencesCCRAS